Helen S. Evans, Henrik Møller European Urology

Slides:

Advertisements

Similar presentations

Benign Prostatic Hyperplasia Dr.Bandar Al Hubaishy Urology Department KAUH.

Advertisements

Genitourinary Blueprint

Volume 72, Issue 1, Pages (July 2017)

MP60-03 PROSTATE CANCER IN THE ELDERLY

Economic Value of the Transurethral Resection in Saline System for Treatment of Benign Prostatic Hyperplasia in England and Wales: Systematic Review,

Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms? Mark J. Speakman European Urology Supplements

Volume 43, Issue 5, Pages (May 2003)

Prostate cancer burden in Central and South America

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Prostate Cancer (C61): 2014 Number of New Cases, Crude and European Age-Standardised (AS) Incidence Rates per 100,000 Population, Males, UK Northern England.

Achieving the Total Approach in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) Management Michael O’Leary European Urology Supplements

Global Trends in Testicular Cancer Incidence and Mortality

Prostate Cancer 2008: Challenges in Diagnosis and Management

Volume 70, Issue 4, Pages (October 2016)

Volume 52, Issue 2, Pages (August 2007)

Volume 71, Issue 5, Pages (May 2017)

Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms? Mark J. Speakman European Urology Supplements

Prostate Cancer Epidemic in Sight?

Volume 45, Issue 4, Pages (April 2004)

Volume 62, Issue 6, Pages (December 2012)

Volume 64, Issue 3, Pages (September 2013)

Volume 43, Issue 5, Pages (May 2003)

Volume 53, Issue 2, Pages (February 2008)

Bladder Cancer: A Major Public Health Issue

Volume 44, Issue 1, Pages (July 2003)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 68, Issue 5, Pages (November 2015)

Sexual Dysfunction and Lower Urinary Tract Symptoms (LUTS) Associated with Benign Prostatic Hyperplasia (BPH) Raymond C. Rosen, Francois Giuliano, Culley.

Volume 52, Issue 3, Pages (September 2007)

Prostate Cancer Detection: A View of the Future

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 54, Issue 5, Pages (November 2008)

Volume 58, Issue 3, Pages (September 2010)

Volume 60, Issue 4, Pages (October 2011)

Counselling the Prostate Cancer Patient

Prostate Cancer Epidemic in Sight?

Thromboembolic Events Following Surgery for Prostate Cancer

Global Burden of Urologic Cancers, 1990–2013

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review Sven van.

Volume 71, Issue 1, Pages (January 2017)

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Richard C. Harkaway European Urology Supplements

Volume 50, Issue 5, Pages (November 2006)

Volume 53, Issue 6, Pages (June 2008)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Transurethral Resection of the Prostate

Testicular Cancer Variations in Time and Space in Europe

Volume 54, Issue 6, Pages (December 2008)

Volume 59, Issue 4, Pages (April 2011)

Volume 72, Issue 1, Pages (July 2017)

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Increasing incidence but decreasing in-hospital mortality of adult Staphylococcus aureus bacteraemia between 1981 and 2000 T. Benfield, F. Espersen,

Prostate Cancer 2008: Challenges in Diagnosis and Management

Role of Transurethral Resection of the Prostate and Biopsy of the Peripheral Zone in the Same Session after Repeated Negative Biopsies in the Diagnosis.

How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia? Vincenzo Mirone

Profile of Silodosin European Urology Supplements

C.G Roehrborn, T McNicholas European Urology Supplements

Manfred Wirth, Peter Iversen, David McLeod, William See

Prostate Cancer (C61): 2014 Number of Deaths, Crude and European Age-Standardised (AS) Mortality Rates per 100,000 Population, Males, UK Northern England.

Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms? Mark J. Speakman European Urology Supplements

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Epidemiology and Demographics of Prostatitis

Quality of life: An outcomes perspective

Does PSA Testing Influence the Natural History of Prostate Cancer?

Volume 54, Issue 1, Pages (July 2008)

Michael Marberger European Urology Supplements

Introduction European Urology Supplements

Vassilios Tzortzis, Stavros Gravas, Jean J.M.C.H. de la Rosette

Presentation transcript:

Recent Trends in Prostate Cancer Incidence and Mortality in Southeast England Helen S. Evans, Henrik Møller European Urology Volume 43, Issue 4, Pages 337-341 (April 2003) DOI: 10.1016/S0302-2838(03)00085-X

Fig. 1 Prostate cancer in southeast England. Age-specific incidence and mortality rates, 1995–1999. European Urology 2003 43, 337-341DOI: (10.1016/S0302-2838(03)00085-X)

Fig. 2 Age-standardised mortality and incidence rate (European standard population) of prostate cancer in southeast England, 1990–1999. European Urology 2003 43, 337-341DOI: (10.1016/S0302-2838(03)00085-X)

Fig. 3 Age-standardised incidence rate (European standard population) of prostate cancer in southeast England, 1990–1999 by stage at diagnosis. European Urology 2003 43, 337-341DOI: (10.1016/S0302-2838(03)00085-X)

Fig. 4 Age-standardised rate of total excision of prostate and capsule of prostate (OPCS4 M61.1) in southeast England, 1990–1998. Source of data: Hospital Episode Statistics (HES), Department of Health. European Urology 2003 43, 337-341DOI: (10.1016/S0302-2838(03)00085-X)

Fig. 5 Number of prescriptions for drugs used in the treatment of benign prostatic hyperplasia (doxasin mesylate, indoramin HCl, prazosin HCl, terazosin HCl, finasteride, alfuzosin HCl, indoramin, tamsulosin HCl) dispensed in England. Source of data: Prescription Cost Analysis (PCA) System, Department of Health. European Urology 2003 43, 337-341DOI: (10.1016/S0302-2838(03)00085-X)

Fig. 6 Age-standardised rate of transurethral resections of the prostate (TURP) in southeast England, 1989–1998. Source of data: Hospital Episode Statistics (HES), Department of Health. European Urology 2003 43, 337-341DOI: (10.1016/S0302-2838(03)00085-X)